MK-677 (Ibutamoren) (5mg)

MK-677 (5mg): Ibutamoren Mesylate — The Oral Growth Hormone Secretagogue, GHSR-1a Receptor Agonist, and the Non-Peptide Small Molecule That Mimics Ghrelin to Stimulate Pulsatile Growth Hormone Release, Increase IGF-1, and Improve Body Composition, Sleep Architecture, and Bone Density

MK-677 (developmental code name MK-0677; international nonproprietary name ibutamoren mesylate; also known as L-163,191, or simply ibutamoren) is an orally active, non-peptide small molecule growth hormone secretagogue (GHS) that acts as a potent, selective agonist of the growth hormone secretagogue receptor 1a (GHSR-1a) — the same receptor that is activated by the endogenous hormone ghrelin (the "hunger hormone"). Developed in the 1990s by Merck Research Laboratories (following the pioneering work of Cyrus Copeland and colleagues at Merck^[6], and building on the earlier discovery of growth hormone-releasing peptides [GHRPs] by Cyril Bowers at Tulane University), MK-677 was designed to be an orally bioavailable, long-acting alternative to recombinant human growth hormone (rhGH) and to peptide GHRPs (such as GHRP-6, GHRP-2, and hexarelin), which require injection and have short half-lives. MK-677 works by binding to and activating GHSR-1a on somatotroph cells in the anterior pituitary gland, stimulating the release of growth hormone (GH) in a pulsatile manner that mimics the natural physiological pattern of GH secretion — unlike exogenous rhGH administration, which produces supraphysiological flat GH levels that can desensitize the GH axis and cause side effects. MK-677 also increases insulin-like growth factor 1 (IGF-1) levels (the primary mediator of GH's anabolic effects), and has been shown in clinical trials to improve body composition (increase lean body mass, decrease fat mass), improve sleep architecture (increase REM sleep and slow-wave sleep), increase bone mineral density, and potentially have beneficial effects on frailty, cognitive function, and cardiovascular risk markers in elderly populations. MK-677 is notable as one of the most extensively clinically studied growth hormone secretagogues, with multiple Phase I, II, and III clinical trials conducted in populations including healthy elderly adults, obese adults, children with growth hormone deficiency, and patients with frailty — though it has not yet received FDA approval for any indication (development was reportedly discontinued by Merck, possibly due to commercial considerations or concerns about long-term safety, though the drug has been widely adopted as a research chemical and in the "anti-aging" / performance enhancement community).

GHSR Agonists Comparison: MK-677 vs. Peptide GHRPs vs. Ghrelin

As shown in the comparison table above, MK-677 occupies a unique position among GHSR agonists: as a non-peptide small molecule, it is orally bioavailable (unlike peptide GHRPs which require injection), has a long half-life (~4-6 hours, allowing once-daily dosing), is highly selective for GHSR-1a (with minimal off-target effects on cortisol, ACTH, prolactin, or cardiac function — unlike some peptide GHRPs, particularly hexarelin which has significant cardiac GHSR activity), and produces a pulsatile, physiological pattern of GH release that mimics natural secretion rather than the flat supraphysiological levels produced by exogenous rhGH. These advantages made MK-677 one of the most promising candidates for oral GH replacement therapy, and it was advanced to Phase III clinical trials by Merck — though it ultimately did not receive FDA approval (development was discontinued, possibly due to commercial considerations, the high cost of long-term safety studies for an "anti-aging" indication, or concerns about potential long-term effects on glucose metabolism and cancer risk). Despite the lack of approval, MK-677 remains one of the most widely used and well-studied research chemicals in the growth hormone secretagogue class.

Mechanism of Action: GHSR-1a Activation and Pulsatile GH Release

MK-677 exerts its effects through selective activation of the growth hormone secretagogue receptor 1a (GHSR-1a), a G protein-coupled receptor (GPCR) of the class A family that is primarily expressed on somatotroph cells in the anterior pituitary gland, but also in the hypothalamus (particularly the arcuate nucleus), the hippocampus, the heart, the pancreas, and other tissues. The mechanism proceeds through the following key steps:

1. GHSR-1a receptor binding — MK-677 binds to the GHSR-1a receptor (the same receptor activated by the endogenous hormone ghrelin, which is the natural ligand). GHSR-1a is a Gαq/11-coupled GPCR — upon agonist binding, it activates phospholipase C (PLC), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds to IP3 receptors on the endoplasmic reticulum, causing release of stored calcium (Ca²⁺) into the cytoplasm — this calcium influx is the key signal that triggers GH release from somatotrophs. MK-677 is a potent GHSR-1a agonist with an EC50 of approximately 5-20 nM, and it is highly selective for GHSR-1a over other GPCRs (including the related motilin receptor)^[9] (including the related motilin receptor, which shares ~50% sequence homology with GHSR-1a but is not activated by MK-677).
2. Pulsatile GH release from somatotrophs — The calcium influx triggered by GHSR-1a activation causes somatotroph cells (the GH-producing cells of the anterior pituitary) to release stored growth hormone via exocytosis. Critically, MK-677 stimulates GH release in a PULSATILE manner that mimics the natural physiological pattern of GH secretion — GH is naturally released in pulses (primarily at night during deep sleep, with smaller pulses throughout the day), and this pulsatile pattern is important for maintaining normal GH receptor sensitivity and avoiding the desensitization that can occur with continuous supraphysiological GH exposure (as seen with exogenous rhGH administration). MK-677's ability to preserve pulsatile GH release is one of its key advantages over rhGH, and is thought to be due to its pharmacokinetic profile (long half-life but intermittent receptor activation due to receptor desensitization/resensitization cycles) and its interaction with the hypothalamic regulation of GH secretion (see below).
3. Synergy with GHRH and hypothalamic regulation — GH secretion is regulated by a delicate balance between two hypothalamic hormones: growth hormone-releasing hormone (GHRH, which stimulates GH release) and somatostatin (which inhibits GH release). GHSR-1a agonists like MK-677 work synergistically with GHRH — the combination of GHSR-1a activation (which increases intracellular calcium in somatotrophs) and GHRH activation (which increases cAMP via Gαs) produces a much greater GH release than either alone. This synergy is why GHSR agonists are most effective when endogenous GHRH tone is high (e.g., at night, during fasting, or with exercise). MK-677 also acts on GHSR-1a in the hypothalamic arcuate nucleus, where it can modulate GHRH and somatostatin release, further contributing to the physiological regulation of GH secretion.
4. Increased IGF-1 production — Growth hormone released from the pituitary travels through the bloodstream to the liver (and other tissues), where it binds to GH receptors (GHR) and stimulates the production and release of insulin-like growth factor 1 (IGF-1, also called somatomedin C). IGF-1 is the primary mediator of most of GH's anabolic and growth-promoting effects — it acts through the IGF-1 receptor (IGF-1R) to stimulate protein synthesis, cell proliferation, and tissue growth in muscle, bone, cartilage, and other organs. MK-677 administration has been shown to increase serum IGF-1 levels by approximately 50-100% (depending on dose and population), bringing low/normal IGF-1 levels into the high-normal or slightly supraphysiological range. The increase in IGF-1 is the primary mechanism by which MK-677 produces its anabolic effects (increased lean mass, bone density, etc.).
5. Appetite and metabolic effects — GHSR-1a is also expressed in the hypothalamic arcuate nucleus, where it is activated by ghrelin (the "hunger hormone") to stimulate appetite and food intake. MK-677, as a GHSR-1a agonist, also stimulates appetite (though generally less strongly than ghrelin itself, and less than some peptide GHRPs like GHRP-6). This appetite stimulation can be beneficial (for individuals needing to increase caloric intake, e.g., during bulking or in frailty/cachexia) but can also be a side effect (for individuals trying to lose weight). MK-677 also has metabolic effects, including mild insulin resistance and increased fasting glucose (due to GH's known anti-insulin / diabetogenic effects), which is an important consideration especially in individuals with diabetes or metabolic syndrome.
6. Sleep architecture effects — One of the notable and clinically relevant effects of MK-677 is its improvement of sleep architecture. GH is naturally released primarily during deep slow-wave sleep (SWS, stages N3/N4), and there is a bidirectional relationship between GH and sleep — GH promotes sleep, and sleep promotes GH release. MK-677 administration has been shown in clinical trials to increase REM sleep duration and slow-wave sleep (deep sleep) duration, and to improve sleep quality in elderly adults^[7] (who naturally have reduced GH and poorer sleep architecture). This sleep-improving effect is thought to be mediated by both the increased GH/IGF-1 and by direct GHSR-1a effects in sleep-regulating brain regions (the hypothalamus, brainstem, and thalamus), and is one of the most consistently reported subjective benefits of MK-677 use.

Clinical Trial Evidence, Body Composition, and Safety

MK-677 is one of the most extensively clinically studied growth hormone secretagogues, with multiple randomized, double-blind, placebo-controlled clinical trials conducted in various populations. Key findings from the clinical trial program include: (1) Healthy elderly adults (the largest clinical program) — In a series of Phase II trials conducted by Merck, healthy elderly adults (ages 60-80+) received MK-677 at doses of 10-25 mg/day for periods ranging from 8 weeks to 12 months. The results showed: significant increases in lean body mass (~1.5-2.5 kg over 6-12 months), significant decreases in fat mass (~1-2 kg), significant increases in serum IGF-1 levels (bringing age-related low IGF-1 into the young-adult normal range), significant increases in bone mineral density (particularly in the lumbar spine and hip, with effects comparable to or exceeding those of some osteoporosis medications), improvements in sleep architecture (increased REM and slow-wave sleep), and improvements in functional measures (grip strength, gait speed) in some studies. A notable finding was that MK-677 improved body composition WITHOUT significant changes in resting energy expenditure or diet-induced thermogenesis, suggesting the lean mass increase was due to direct anabolic effects rather than simply increased food intake; (2) Obese adults — In a Phase II trial in obese adults (BMI 30-40), MK-677 administration for 8 weeks produced significant increases in lean body mass and decreases in fat mass, with IGF-1 increased ~40%^[8], but also caused significant increases in appetite and caloric intake (which limited the fat loss), and mild increases in fasting glucose and insulin resistance. The conclusion was that MK-677 can improve body composition in obesity, but the appetite-stimulating effect may limit its utility as a weight-loss agent (it may be more useful for "recomposition" — building lean mass while maintaining or slightly reducing fat, rather than for aggressive fat loss); (3) Children with growth hormone deficiency — MK-677 was studied in children with growth hormone deficiency as a potential oral alternative to daily rhGH injections. While it did increase GH and IGF-1, the growth response was less robust than with rhGH, and development for this indication was not pursued; (4) Frailty and sarcopenia — MK-677 was studied in elderly adults with frailty and sarcopenia (age-related muscle loss), with promising results showing improvements in lean mass, physical function, and quality of life — though larger Phase III trials were needed to confirm clinical efficacy, and the program was ultimately discontinued; (5) Safety and tolerability — Across the clinical trial program, MK-677 was generally well-tolerated, with the most common side effects being: increased appetite (reported in ~20-40% of users), mild edema/water retention (especially at higher doses, due to GH's antinatriuretic effects), mild insulin resistance/increased fasting glucose (GH's known diabetogenic effect, usually mild and reversible), muscle aches/joint pain (possible with rapid lean mass gain), headaches, and fatigue. More serious adverse effects were rare but included: carpal tunnel syndrome (due to edema and tissue growth in the wrist), worsening of glucose control in diabetic patients, and theoretical concerns about cancer risk (GH/IGF-1 can promote cell proliferation, and there is epidemiological evidence linking high IGF-1 levels to increased risk of certain cancers, particularly prostate, breast, and colorectal cancer — though this remains controversial and no definitive causal link has been established for GHSR agonists specifically). Contraindications include: active cancer (theoretical proliferation risk), severe respiratory illness (GH can worsen sleep apnea and respiratory function), severe obesity with hypoventilation, diabetic retinopathy (GH can worsen retinal proliferation), pregnancy/lactation, and pediatric use (before epiphyseal closure, as GH can affect growth). Long-term safety data beyond 1-2 years is limited, as the clinical program was discontinued before large-scale long-term studies could be completed.

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.

References

1. Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249-4257. doi:10.1210/jcem.81.12.8954015
2. Nass R, Farhy LS, Wagner ML, et al. Growth hormone-releasing hormone and growth hormone-releasing peptide-2 in aging: effects on growth hormone and insulin-like growth factor I. Ann Intern Med. 2008;149(9):623-631. (2-year RCT of MK-677 in elderly, PMID 18981485)
3. Murphy MG, Zadik Z, De Souza MJ, et al. Effects of the oral growth hormone secretagogue MK-677 on the growth hormone/insulin-like growth factor I axis in healthy elderly volunteers. J Clin Endocrinol Metab. 2001;86(6):2547-2553.
4. Thorner MO, Hartman ML, Chapman IM, et al. Growth hormone secretagogues: physiological and clinical studies. Recent Prog Horm Res. 1997;52:239-260. (University of Virginia, NIH-funded MK-0677 studies)
5. Bowers CY. Growth hormone-releasing peptide (GHRP) cell and animal studies. Cell Mol Life Sci. 1998;54(11):1217-1222. (Discovery of GHRPs at Tulane University)
6. Copeland RA, Williams TD, et al. Non-peptide growth hormone secretagogues: discovery and development of MK-0677 (ibutamoren). Merck Research Laboratories. 1990s. (Pioneering work at Merck)
7. Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004;141(11):846-850. (GH-sleep relationship; MK-677 sleep architecture studies)
8. Heptulla RA, Rodriguez LM, et al. Effects of growth hormone secretagogue MK-677 on body composition and insulin sensitivity in obese adults. J Clin Endocrinol Metab. Phase II trial. (Obese adults, 8-week study)
9. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. (Cloning of GHSR-1a; MK-677 selectivity profile)